The impact of genomic and proteomic technologies on the development of new cancer drugs

被引：13
作者：
Workman, P [1 ]
机构：
[1] Inst Canc Res, Ctr Canc Therapeut, Canc Res UK, Sutton, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2002年 / 13卷
关键词：
D O I：
10.1093/annonc/mdf648
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：115 / 124
页数：10
相关论文
共 64 条
  • [1] Proteasome inhibition: a novel approach to cancer therapy
    Adams, J
    [J]. TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) : S49 - S54
  • [2] [Anonymous], 2001, LANCET, V357, P489
  • [3] [Anonymous], 1985, AUST FEMINIST STUD, DOI DOI 10.1080/08164649.1985.10382902
  • [4] Our genome unveiled
    Baltimore, D
    [J]. NATURE, 2001, 409 (6822) : 814 - 816
  • [5] BLACKSTOCK W, 2000, PROTEOMICS TRENDS GU
  • [6] New developments in microarray technology
    Blohm, DH
    Guiseppi-Elie, A
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2001, 12 (01) : 41 - 47
  • [7] Genomic biology
    Brent, R
    [J]. CELL, 2000, 100 (01) : 169 - 183
  • [8] Epigenomics and epigenetic therapy of cancer
    Brown, R
    Strathdee, G
    [J]. TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) : S43 - S48
  • [9] Brown T.A., 1999, Genomes
  • [10] Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential
    Clarke, PA
    Poele, RT
    Wooster, R
    Workman, P
    [J]. BIOCHEMICAL PHARMACOLOGY, 2001, 62 (10) : 1311 - 1336
1234567